摘要
目的 探究甲泼尼龙联合艾拉莫德治疗干燥综合征的疗效。方法 选取收治的84例干燥综合征患者,依据随机数字表法分为对照组和观察组,每组42例。对照组患者予以甲泼尼龙联合硫酸羟氯喹治疗,观察组患者予以甲泼尼龙联合艾拉莫德治疗。比较2组患者的临床疗效、干燥综合征患者报告指数(EULAR Sj?gren’s syndrome patient reported index,ESSPRI)、干燥综合征疾病活动指数(EULAR Sj?gren’s syndrome disease activity index,ESSDAI)、泪液分泌试验(Schirmeri)、唾液流速、血清指标及不良反应。结果 观察组的治疗有效率(90.48%)显著高于对照组(71.43%),P<0.05。治疗后,2组的ESSPRI、ESSDAI评分均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);2组的Schirmeri值、唾液流速均显著升高(P<0.05),且观察组显著高于对照组(P<0.05);2组的白细胞介素-17(interleukin,IL-17)、血沉(erythrocyte sedimentation rate,ESR)、C-反应蛋白(C-reactive protein, CRP)及免疫球蛋白G(immunoglobulin G,IgG)水平均显著降低(P<0.05),且观察组显著低于对照组(P<0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论 甲泼尼龙联合艾拉莫德治疗干燥综合征疗效确切,能显著改善患者的临床症状,减轻炎症反应,改善淋巴细胞浸润,且安全性高。
Objective To investigate the effect of methylprednisolone combined with iguratimod in the treatment of Sjögren’s syndrome.Methods A total of 84 patients with Sjögren’s syndrome were randomly assigned to a control group and a observation group,with 42 patients in each group.Patients in the control group were treated with methylprednisolone combined withhydroxychloroquine sulfate,while those in the observation group were treated with methylprednisolone combined with iguratimod.The clinical effect,the EULAR Sjögren’s syndrome patient reported index(ESSPRI),the EULAR Sjögren’s syndrome disease activity index(ESSDAI),Schirmeri test,salivary flow rate,serum indicators and the incidence of adverse reactions were compared between the 2 groups.Results The treatment response rate in the observation group(90.48%)was significantly higher than that in the control group(71.43%),P<0.05.After treatment,the ESSPRI scores and ESSDAI scores of the 2 groups decreased,and the observation group had lower scores than the control group(P<0.05).Schirmeri test values and salivary flow rates in the 2 groups increased,and the 2 indicators in the observation group were higher than those in the control group(P<0.05).The levels of interleukin-17(IL-17),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP)and immunoglobulin G(IgG)in the 2 groups decreased,and the levels in the observation group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Methylprednisolone combined with iguratimod is effective in the treatment of Sjögren’s syndrome,which can significantly relieve clinical symptoms and inflammatory reactions,and improve lymphocytes infiltration,with high safety.
作者
桂雅迪
章雯
包先国
徐佳佳
王雷
GUI Yadi;ZHANG Wen;BAO Xianguo;XU Jiajia;WANG Lei(Department of Endocrinology,Lishui District People’s Hospital,Nanjing 211299,China)
出处
《西北药学杂志》
CAS
2024年第5期207-211,共5页
Northwest Pharmaceutical Journal
基金
南京市医学科技发展专项资金资助项目(编号:YKK21205)。
关键词
干燥综合征
甲泼尼龙
艾拉莫德
血清白细胞介素-17
血沉
C-反应蛋白
免疫球蛋白
Sjögren’s syndrome
methylprednisolone
iguratimod
serum interleukin-17
erythrocyte sedimentation rate
C-reactive protein
immunoglobulin
